ALPN News and Press, Alpine Immune Sciences Inc. From 09/15/20

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summi...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the H.C. Wainwright 22nd Annual Global Investment Conference on T...

Alpine Immune Sciences, Inc. (ALPN) Q2 2020 Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Laurence Watts - Investor Relations Mitchell Gold - Chairman & Chief Executive Officer Remy Durand - Senior Vice President, Business Development & Corporat...

Alpine Immune Sciences (NASDAQ: ALPN ) : Q2 GAAP EPS of -$0.53. More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Signed option to license worldwide rights to ALPN-101 with AbbVie - - Received $60 million upfront cash payment from AbbVie; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones - - Dosed first pati...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesd...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2020 financial results on Tuesday, August 11, 2020 af...

Alpine Immune Sciences ( ALPN +1.6% ) to offer common and prefunded warrant units at $10.1175/unit, for gross proceeds of ~$60M. More news on: Alpine Immune Sciences, Inc., Healthcare stocks news, , Read more ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common units a...

The following medical companies have filed for mixed shelf offerings: More news on: Ardelyx, Inc., Vaxart, Inc., Alpine Immune Sciences, Inc., Healthcare stocks news, , Read more ...